ClinicalTrialsFinder

Relapsed/Refractory Multiple Myeloma(MM) Clinical Trials in Xi’an, Shanxi

1 recruitingXi’an, Shanxi, China

Showing 1–1 of 1 trials

Recruiting
Phase 1

Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma(MM)
Xi'an No.3 Hospital18 enrolled1 locationNCT07139509